Serum biomarkers for mycosis fungoidesm, Sézary syndrome, and cutaneous B cell lymphoma patients during and after treatments - S-MISR

niversitätsklinikum Münster0 个研究点目标入组 130 人开始时间: 2022年9月27日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Histologically-confirmed diagnosis of primary cutaneous T-cell and B-cell Lymphoma (Mycosis fungoides, Sezary Syndrom, pcALCL, FL, MZL, DLBCL-leg type, others)
•Insufficient response to at least one prior systemic or topical therapy
•Age = 18 years
•Wash-out period of 4 weeks before systemic therapy and 2 weeks before topical therapy
•Written informed consent for study participation
•Life expectancy > 6 months
•Eastern Cooperative Oncology Group score = 2

•Prior or active skin malignancy (except for completely excised, non-invasive basal cell or squamous cell carcinoma diagnosed > 2 years prior to enrollment)
•Uncontrolled bacterial or fungal infection at time of enrollment
•Active or prior autoimmune disease requiring systemic treatment
•Active or prior non-infectious pneumonitis requiring steroids or pulmonary fibrosis
•Pregnancy or lactation; Women of childbearing age with reproductive potential should use adequate birth control measures during the study treatment period and for at least 5 months after treatment.
•Patients awaiting stem cell transplantation

发起方

niversitätsklinikum Münster